# This Study Consists of Two Study Parts Conducted Under a Single IRB. Part I: Short Term ApoE-dependent Cerebral Blood Flow Response to Sirolimus in Cognitively Normal Adults Part II: Short Term ApoE-dependent Cerebral Blood Flow and Lung Perfusion Response to Sirolimus in Cognitively Normal Adults

> **NCT05386914** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Missouri-Columbia** · enrollment: 205 (estimated)

## Conditions studied

- Genetic Predisposition to Disease
- Healthy Volunteers

## Interventions

- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT05386914
- **Lead sponsor:** University of Missouri-Columbia
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-02
- **Primary completion:** 2025-09-19
- **Final completion:** 2027-12
- **Target enrollment:** 205 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05386914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05386914, "This Study Consists of Two Study Parts Conducted Under a Single IRB. Part I: Short Term ApoE-dependent Cerebral Blood Flow Response to Sirolimus in Cognitively Normal Adults Part II: Short Term ApoE-dependent Cerebral Blood Flow and Lung Perfusion Response to Sirolimus in Cognitively Normal Adults". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05386914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*